百利科技(603959.SH):與杉杉能源簽訂8億元三元材料建設項目合同
格隆匯5月21日丨百利科技(603959.SH)公吿,公司於2021年1月14日披露了《百利科技項目中標公吿》,公司中標湖南杉杉能源科技股份有限公司(“杉杉能源”)《長沙基地二期工程動力鋰電池三元材料建設項目》設備與產線集成及配套供應商。
2021年5月21日,公司與杉杉能源簽署了《湖南杉杉能源科技股份有限公司長沙基地二期工程動力鋰電池三元材料建設項目承包合同》。此合同總價為人民幣8億元,佔公司2020年度經審計營業收入的56.97%。如合同按期履行,預計會對公司當期及未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.